

Eritrea Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Eritrea					
2. Grant number: 1821-ERI-04a-X; 07-ERI-08b-Y					
3. Date of Decision Letter: 6 March 2019					
4. Date of the Partnership Framework Agreement: 16 April 2013					
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine					
6. Vaccine type: Pentavalent					
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 doses per vial, LIQUID					
8. Programme duration¹: 2008 -2021					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2008-2018	2019	2020	2021	Total ²
Programme Budget (US\$)	US\$7,243,380 ³	US\$242,000	US\$333,500	US\$342,000	US\$8,160,880
10. Vaccine introduction grant (in US\$): US\$ 100,000 disbursed on 16 March 2007					
11. Product switch grant: Not applicable					
12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴					
Type of supplies to be purchased with Gavi funds in each year	2008-2018		2019		
Number of Pentavalent vaccines doses			215,500		
Annual Amounts (US\$)	US\$7,243,380 ⁵		US\$242,000		
13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
14. Self-procurement: N/A					
15. Co-financing obligations: Reference code: 1821-ERI-04a-X-C According to the co-financing policy, the Country falls within the group Initial self-financing.					

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019	2020	2021
Number of vaccine doses	46,900	64,700	66,300
Value of vaccine doses (US\$)	US\$49,167	US\$67,843	US\$69,586
Total co-financing payments (US\$) (including freight)	US\$52,500	US\$72,500	US\$74,500

16. Operational support for campaigns: Not applicable

17. Additional reporting requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2019 15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

18. Financial clarifications: Not applicable

19. Other conditions: Not applicable

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
6 March 2019